United States Gonorrhea Therapeutics Market is Expected to Reach USD 892.3 Million by 2031
Published | January 2021
According to BlueWeave Consulting, the United States gonorrhea therapeutics market is estimated to
have reached USD 456.8 million in 2020 and is further projected to reach USD
892.3 million by 2027, growing at a CAGR of 6.2% during 2021-2031 (forecast
period). Preference for NAATs over traditional cultures has grown significantly
in recent years owing to their improved sensitivity and selectivity for
Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. Such increased
availability and adoption of testing modalities are driving the demand for
gonorrhea therapeutics. The increasing prevalence of gonorrhea coupled with the
rising public awareness about STDs (Sexually-Transmitted Diseases), and
advances in relevant diagnostic methods, are the key growth determinants of the
gonorrhea therapeutics market.
Growing prevalence of
STDs increases patient awareness through national campaigns and growing
government initiatives
The rise in patient
awareness, such as education campaigns and increasing government initiatives,
are expected to show lucrative opportunities for market players. Moreover, the
rising population having increased casual sex partners is also feeding market
growth. The Centers for Disease Control and Prevention (CDC) assesses that
there are about 20 million new STD diseases each year—almost half of them among
young people ages 15 to 24. Along with the government, multiple non-profit
organizations are also organizing awareness campaigns against sexually
transmitted diseases. For instance, CDC organized an STD Awareness Week from
April 12- 18, 2020.
Hefty financial
allocations for R&D activities
Currently, there is no
vaccine for the treatment of Gonorrhea due to which companies are heavily
investing to gain a competitive edge and to hold the market position. For
instance, GSK started a phase III clinical program investigating gepotidacin,
the first in a new chemical class of antibiotics called triazaacenaphthylene
bacterial topoisomerase inhibitors, in patients with uncomplicated urinary
tract infection (uUTI, also known as acute cystitis) and urogenital gonorrhea
(GC). Entasis Therapeutics at the World Anti-Microbial Resistance Congress has
registered the first patient in a global phase 3 trial of oral zoliflodacin for
the treatment of uncomplicated gonorrhea.
Injectables segment
occupy the major share of the United States Gonorrhea Therapeutics market
Based on the route of
administration, the United States gonorrhea therapeutics market is segregated
into oral & injectable. In 2019, the Injectables market segment recorded a
major share in the market. Due to emerging strains of drug-resistant Neisseria,
the Centers for Disease Control and Prevention recommends that uncomplicated
gonorrhea be treated with the antibiotic ceftriaxone given as an injection with
oral azithromycin, erythromycin, clarithromycin, azithromycin, and
roxithromycin are the most recommended macrolides. Tetracycline is an
antibiotic that fights infection caused by bacteria such as Neisseria gonorrhea
and is the second primary drug after macrolides.
United States Gonorrhea
Therapeutics market: Regional insights
Growing awareness about
sexually transmitted diseases and the available cure for the same is supposed
to help newer diagnostic tools for gonorrhea over the traditional method of
detection. Rapidly changing lifestyles and the involvement of multiple sex
partners is the factor anticipated to boost the market in the future. Though
weak healthcare structure and low disposable incomes may hamper the market in
the country, the market growth rate is expected to stabilize owing to the
growing number of hospitals, commercial labs, and newer diagnostic techniques
with cost-saving and faster procedures.
The leading
players” in the United States gonorrhea therapeutics
market include GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc,
AstraZeneca, Hologic, Inc., Danaher, Abbott, Becton Dickinson and Company, F.
Hoffmann-La Roche Ltd., Alopexx Pharmaceuticals, Melinta Therapeutics &
other prominent players. These industry players implement various strategies
such as mergers & acquisitions, partnerships, and new product launches to
enhance profitability and company growth.
The in-depth analysis of
the report provides information about growth potential, upcoming trends, and
statistics of the United States gonorrhea therapeutics market size &
forecast. The report promises to provide recent technology trends of the
gonorrhea therapeutics market and industry insights that help decision-makers
to make sound strategic decisions. Furthermore, the report also analyzes the
growth drivers, challenges, and competitive dynamics of the market.
About Us
Blue Weave Consulting
provides all kinds of Market Intelligence (MI) Solutions to businesses
regarding various products and services online & offline. We offer
comprehensive market research reports by analyzing both qualitative and
quantitative data to boost up the performance of your business solution. BWC
has built its reputation from the scratches by delivering quality inputs and
nourishing long-lasting relationships with its clients. We are one of the
promising digital MI solutions company providing agile assistance to make your
business endeavors successful.
